Oncology · Supportive CareRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Leucovorin Calcium by Ingenus Pharmaceuticals

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:33:14 PM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Ingenus Pharmaceuticals' ANDA for Leucovorin Calcium signifies a potential shift in the oncology supportive care market, increasing competition against existing branded products. Portfolio teams must evaluate the implications for market share and pricing strategies as this generic product approaches market entry. Regulatory context from FDA (FDA AP — LEUCOVORIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on market share and pricing strategies for existing Leucovorin products. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · Supportive Care, 8 regulatory and 4 competitive items passed relevance filtering for Ingenus Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This acceptance may increase competition in the supportive care market for oncology, particularly against branded versions of Leucovorin.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEUCOVORIN CALCIUM (SUPPL) (FDA). Regulatory pathway relevance (nda). While the ANDA has been accepted, the timeline for final approval and subsequent market entry remains critical to assess regulatory compliance and competitive positioning.

Key Risks

Elevated medium regulatory exposure for Ingenus Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a generic version of Leucovorin Calcium could lead to price reductions and market share erosion for existing branded products, impacting revenue streams in the oncology supportive care segment.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Ingenus Pharmaceuticals may improve if Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Ingenus Pharmaceuticals may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and market entry of Ingenus' Leucovorin Calcium.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Data Collection, Clinical Care and Interventions in CCR, NCI
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Disparities in Behavioral Health Treatment for Children in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nurses' perspectives on medication safety for Swedish community-dwelling older adults in primary care.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ingenus Pharmaceuticals

Commercial impact

medium

The introduction of a generic version of Leucovorin Calcium could lead to price reductions and market share erosion for existing branded products, impacting revenue streams in the oncology supportive care segment.

Regulatory impact

medium

While the ANDA has been accepted, the timeline for final approval and subsequent market entry remains critical to assess regulatory compliance and competitive positioning.

What to watch

Monitor the timeline for final approval and market entry of Ingenus' Leucovorin Calcium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.